AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03200639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined training
Description: The CT and CTc protocol (total length time \~60 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by 30-min walk at 70% of maximum heart rate or Borg Scale at 5-6 following resistance exercises (RE: 45-degree half squat, bench press, leg curl, rowing machine and unilateral leg extension) at 70% of one repetition maximum (1RM) with three sets of 8-12 repetitions and 1.5 min rest interval between sets and exercises. If the volunteer exceeded or did not reach the walk intensity, the volunteer was stimulated by to decrease or increase the walk speed, respectively. Regarding the resistance exercises, the load was adjusted in the 6th week with the 1RM test to ensure the 70% of 1RM between 8-12 repetitions.
Study NCT03200639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training with body weight
Description: The HIITBW and HIITBWc protocol (total length time \~28 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by ten sets of 60 s of high (vigorous) intensity exercises at 80-95% of HRmax or Borg Scale at 8-9 (i.e. 30s of stepping up and down on a step and 30s of squatting up and down as fast as possible) interspersed with a recovery of 60 s of light walk (\<60% of HRmax or Borg Scale at \<5). To ensure vigorous zone of all sets, if the volunteer exceeded or did not reach the vigorous zone the volunteer was stimulated by the fitness professionals to decrease or increase the number of steps and squats, respectively.
Study NCT03200639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training with body weight
Description: The HIITBW and HIITBWc protocol (total length time \~28 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by ten sets of 60 s of high (vigorous) intensity exercises at 80-95% of HRmax or Borg Scale at 8-9 (i.e. 30s of stepping up and down on a step and 30s of squatting up and down as fast as possible) interspersed with a recovery of 60 s of light walk (\<60% of HRmax or Borg Scale at \<5). To ensure vigorous zone of all sets, if the volunteer exceeded or did not reach the vigorous zone the volunteer was stimulated by the fitness professionals to decrease or increase the number of steps and squats, respectively.
Study NCT05383443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously).
Study NCT05383443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training (group) or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic.
Study NCT05383443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly).
Study NCT05383443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capacitation to deal with cognitive decline
Description: This component will be based on in-person 60-minute group sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
Study NCT05383443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnosis and correction of hearing impairment
Description: This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
Study NCT05383443 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (once a week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously).
Study NCT05383443 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: In-person group training (monthly): 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher.
Study NCT05383443 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants. The participants will have the opportunity to consume the prepared meals at home.
Study NCT05383443 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Capacitation to deal with cognitive decline
Description: In-person group 60-minute sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
Study NCT05383443 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis and correction of hearing impairment
Description: This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
Study NCT03584997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ABB And Autogenous Particulate
Description: Mixing the autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
Study NCT03584997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF, ABB & Autogenous Particulate
Description: adding an injectable platelets rich fibrin to a Mixture of autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
Study NCT03429985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRRM Intervention
Description: Fathers Raising Responsible Men (FRRM) is designed to facilitate important paternal parenting behaviors that influence adolescent decision-making. FRRM incorporates a novel, theoretically-based intervention highlighting the important and influential role that fathers have on the development and life trajectories of adolescent males.
Study NCT01083979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomes
Description: Intravesical instillation
Study NCT03263130 — intervention group
Intervention type: OTHER
Intervention: As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap
Study NCT04011826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Trial nasal mask (F&P)
Description: This trial nasal mask will serve as the participant's primary PAP/BPAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial nasal mask as their primary PAP/BPAP therapy mask for 6 months after Visit 3.
Study NCT02138305 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ComboMap XT Guidewire
Description: Intracoronary pressure and flow measurements
Study NCT02138305 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 'SPY' NIRF During CABG
Description: FDA approved use of injection of indocyanine green for the purposes of performing pre and post coronary grafting graft patency and perfusion assessment with the SPY near infra red fluorescence system
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-11
Description: Flavor variant CSD190601-11 of a 1.5% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-12
Description: Flavor variant CSD190601-12 of a 1.5% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-13
Description: Flavor variant CSD190601-13 of a 1.5% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-14
Description: Flavor variant CSD190601-14 of a 1.5% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-15
Description: Flavor variant CSD190601-15 of a 1.5% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-16
Description: Flavor variant CSD190601-16 of a 1.5% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-17
Description: Flavor variant CSD190601-17 of a 1.5% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-21
Description: Flavor variant CSD190601-21 of a 3.0% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-22
Description: Flavor variant CSD190601-22 of a 3.0% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-23
Description: Flavor variant CSD190601-23 of a 3.0% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-24
Description: Flavor variant CSD190601-24 of a 3.0% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-25
Description: Flavor variant CSD190601-25 of a 3.0% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-26
Description: Flavor variant CSD190601-26 of a 3.0% nicotine ENDS product
Study NCT04308434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD190601-27
Description: Flavor variant CSD190601-27 of a 3.0% nicotine ENDS product
Study NCT02916641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu
Study NCT02916641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Study NCT02916641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Study NCT04308460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthrocentesis
Description: lavage of the temporomandibular joint was done
Study NCT04308460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative arthroscopy
Description: operative intervention inside the temporomandibular joint was done using arthroscope
Study NCT03262571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Description: Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
Study NCT03262571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Lung ultrasound
Description: Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
Study NCT03404531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Messages Intervention Group
Description: The Social Media Messages Intervention Group will receive theoretically-grounded messages through social media in order to encourage participants to regularly access the newly developed, culturally-tailored website that includes information about treatment as prevention and pre-exposure prophylaxis.
Study NCT03404531 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Website Only Group
Description: The Website Only group will have access to the newly developed, culturally-tailored website but will not receive social media messages.
Study NCT05300230 — intervention group
Intervention type: DEVICE
Intervention: Neuro Zti cochlear implant and Neuro 2 sound processor
Description: The study will consist in 3 visits:~* Visit 1: it will be carried out the first contact and learning the measurement procedure.~* Visit 2: it will be evaluated the speech perception and the measurement of the pupil dilatation in silence and noise conditions.~* Visit 3: it will be analysed the effect of the change in the cochlear implant programming parameters.
Study NCT02708849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Study NCT02708849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
Study NCT01443897 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mushrooms
Description: untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA
Study NCT01443897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mushrooms
Description: untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA
Study NCT01443897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UVB-treated mushrooms, 400 IU vitamin D2
Description: UVB-treated button mushrooms, 400 IU vitamin D2 per 1/2 cup serving, obtained from Monterey Mushrooms, Monterey, CA
Study NCT01443897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UVB-treated mushrooms, 1,000 IU vitamin D2
Description: UVB-treated button mushrooms, 1,000 IU vitamin D2 per 1/c serving, obtained from Monterey Mushrooms, Monterey, CA
Study NCT01948050 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: non-invasive transcranial direct current stimulation (tDCS)
Study NCT02008669 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: A blood sample will be taken from each patient and the following parameters will be assessed : magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.
Study NCT02008669 — intervention group
Intervention type: OTHER
Intervention: Gustatory sensitivity test using Taste strips
Description: 16 Taste Strips impregnated with 4 flavors (sweet, sour, salty, bitter, each flavor present at 4 different concentrations), are offered to the patient one after the other in a so-called pseudorandomized sequence. The task of the patient is to choose one of the following answers: sweet / sour / salty / bitter / no taste.~Each correct answer is granted one point. In addition to the impregnated strips, two tasteless strips can be integrated in the examination at any point of time (no point)
Study NCT02008669 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Evaluation of the following parameters by validated questionnaires (name of the questionnaire in bracket):~* Fatigue (EMIF-SEP)~* Dysphagia (DYMUS)~* Food intake (semi-structured questionnaire)~* Depression (BDI-II)~* Daily energy expenditure (NAP)~* Visual analog scale to study quality of sleep
Study NCT01411566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills trainig for patients with dual diagnosis
Description: Skills trainig for patients with dual diagnosis
Study NCT01411566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: regular treatment
Description: regular treatment
Study NCT01203943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-930
Description: CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
Study NCT01203943 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01203943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-930
Description: CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
Study NCT01203943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-930
Description: C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
Study NCT03930940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric autocontrol device with cuffs placed on arm and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 4 to 5 times.
Study NCT03930940 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regular treatment
Description: Regular treatment is based on associated guidelines for ICH.
Study NCT03930940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular treatment
Description: Regular treatment is based on associated guidelines for ICH.
Study NCT01233934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine 1% Gel
Description: Small amount applied over the lesion twice a day for 7 days.
Study NCT02708849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
Study NCT02708849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dose placebo
Study NCT00644930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the application of NPPV
Description: ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated. BIPAP Vision machine (Respironics, PA, USA) were used for NPPV.
Study NCT03575117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common-Sense Model (CSM) Be Well
Description: Theoretically informed text messages and images that cover how physical activity is linked to decreasing colorectal cancer risk.
Study NCT03575117 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACS usual messages
Description: Information distributed by the American Cancer Society as information on the link between physical activity and cancer risk (source: www.cancer.org)
Study NCT03575117 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NCI HealthyYouTXT--Get Active (HYT--GA)
Description: Text messaging program developed by National Cancer Society (NCI). It is a free SMS program that promotes physical activity.
Study NCT01233934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine 1% Cream
Description: Small amount applied over the lesion twice a day for 7 days.
Study NCT00154115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosimendan
Description: Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
Study NCT00154115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT02715518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI using 2nd generation drug-eluting stent
Description: Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.~1. FFR-guided strategy arm~2. Angiography-guided strategy arm
Study NCT03575117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NCI HealthyYouTXT--Get Active (HYT--GA)
Description: Text messaging program developed by National Cancer Society (NCI). It is a free SMS program that promotes physical activity.
Study NCT01408550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPB-01
Description: Intravenous immunoglobulin
Study NCT01408550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline
Study NCT01957163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
Study NCT01957163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
Study NCT01957163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
Study NCT01957163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The matching placebo DPI identical in appearance to the inhaler containing active study medication.
Study NCT01823406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp (normal blood sugar clamp) for 4 hours
Study NCT02132923 — intervention group
Intervention type: BIOLOGICAL
Intervention: No intervention
Description: This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.